Colgate-Palmolive India shares upgraded by Nomura, but majority analysts still say ‘sell’

Of the 31 analysts who have coverage on Colgate-Palmolive India, eight have a “buy” rating, 12 have a “hold” rating and 11 have a “sell” rating.

Of the 31 analysts who have coverage on Colgate-Palmolive India, eight have a “buy” rating, 12 have a “hold” rating and 11 have a “sell” rating.

DSP Mutual Fund says now is the time to buy rupee assets, citing competitive REER, strong services exports, remittances and attractive large cap valuations.

Indian rupee strengthens to two week high as Iran tensions ease, RBI Governor Sanjay Malhotra signals support, lower oil prices and Asian gains aid recovery.

Sources tell CNBC-TV18 that the promoter entity is the likely seller in the Premier Energies block deal, while multiple Foreign Institutional Investors, and Mutual Funds were buyers.

Kotak Institutional Equities, who is bearish on Divi’s Laboratories, said that the stock’s current valuations of 49 times its estimated price-to-earnings ratio for FY28, is already pricing in growth potential.

Petrol price raised by ₹2.61 per litre and diesel by ₹2.71 per litre on May 25, weekly hikes reach ₹4.35 and ₹4.53 per litre amid Brent above 100 and reduced OMC losses

Japan’s Nikkei index surged 2.7%, while Brent declined over 4.5% to around $98.8 a barrel on expectations that a deal would reopen the Strait of Hormuz.

Gold and silver prices surge as a weaker US dollar, lower oil and US Iran peace talks boost safe haven demand, with markets eyeing Fed policy signals.

It was a busy weekend for pharma stocks as four of them — Divi’s Laboratories, Fortis Healthcare, Torrent Pharma and Narayana Hrudayalaya — reported their quarterly results. Meanwhile, Lupin marked its entry into the Chinese market, while Glenmark Pharma’s US…

RBI Governor Sanjay Malhotra says the rupee may now be undervalued, highlights REER metrics, BoP stability and measured forex interventions amid global risks.